长效促性腺激素释放激素类似物治疗晚期前列腺癌患者中早期肿瘤恶化的重要性。 - Suppr

Suppr

超能文献

Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.

作者信息

Waxman J, Man A, Hendry W F, Whitfield H N, Besser G M, Tiptaft R C, Paris A M, Oliver R T

出版信息

Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1387-8. doi: 10.1136/bmj.291.6506.1387.

DOI:10.1136/bmj.291.6506.1387

PMID:2933122

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1419017/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a89/1419017/e3f1bd154d5b/bmjcred00474-0021-a.jpg

相似文献

Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.长效促性腺激素释放激素类似物治疗晚期前列腺癌患者中早期肿瘤恶化的重要性。

Br Med J (Clin Res Ed). 1985 Nov 16;291(6506):1387-8. doi: 10.1136/bmj.291.6506.1387.

Early tumor exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone.接受促性腺激素释放激素长效类似物治疗的患者早期肿瘤恶化

Br Med J (Clin Res Ed). 1985 Dec 7;291(6509):1645. doi: 10.1136/bmj.291.6509.1645.

Disease flare induced by luteinising hormone releasing hormone analogues in cancer patients.癌症患者中促黄体生成素释放激素类似物诱发的疾病发作。

Lancet. 1984 Jun 9;1(8389):1302. doi: 10.1016/s0140-6736(84)92488-7.

Gonadotropin-releasing hormone analogs and prostatic cancer.促性腺激素释放激素类似物与前列腺癌

Crit Rev Oncol Hematol. 1988;8(1):1-26. doi: 10.1016/s1040-8428(88)80003-9.

[Treatment of carcinoma of the prostate with analogs of LHRH].

Rev Clin Esp. 1986 Nov;179(8):407-11.

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.促性腺激素释放激素类似物治疗晚期前列腺癌。

Br Med J (Clin Res Ed). 1983 Apr 23;286(6374):1309-12. doi: 10.1136/bmj.286.6374.1309.

LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade.

Recent Results Cancer Res. 1990;118:174-85. doi: 10.1007/978-3-642-83816-3_17.

Gonadotrophin hormone releasing analogues open new doors in cancer treatment.促性腺激素释放类似物为癌症治疗打开了新的大门。

Br Med J (Clin Res Ed). 1987 Oct 31;295(6606):1084-5. doi: 10.1136/bmj.295.6606.1084.

[Dramatic aggravation of prostatic cancer at the onset of treatment with an LHRH agonist].[使用促性腺激素释放激素（LHRH）激动剂治疗开始时前列腺癌的戏剧性加重]

Presse Med. 1985 May 25;14(21):1200-1.

Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.

Prog Clin Biol Res. 1987;243A:207-20.

引用本文的文献

Erectile dysfunction associated with prostate cancer treatment and therapeutic advances: a narrative review.与前列腺癌治疗相关的勃起功能障碍及治疗进展：一项叙述性综述

Transl Androl Urol. 2024 Nov 30;13(11):2625-2643. doi: 10.21037/tau-24-514. Epub 2024 Nov 28.

Cardiovascular Toxicity of Androgen Deprivation Therapy.雄激素剥夺治疗的心血管毒性。

Curr Cardiol Rep. 2021 Jul 3;23(8):109. doi: 10.1007/s11886-021-01561-9.

Hormonal Therapy for Prostate Cancer.前列腺癌的激素治疗。

Endocr Rev. 2021 May 25;42(3):354-373. doi: 10.1210/endrev/bnab002.

GnRH-R-Targeted Lytic Peptide Sensitizes Wild-type Ovarian Cancer to PARP Inhibition.GnRH-R 靶向溶瘤肽使野生型卵巢癌对 PARP 抑制敏感。

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study.度他雄胺治疗前列腺癌日本受试者的 3 个月给药方案的疗效和安全性：一项 III 期研究。

Cancer Sci. 2018 Jun;109(6):1920-1929. doi: 10.1111/cas.13600. Epub 2018 May 23.

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.地加瑞克治疗与前列腺癌患者的糖尿病和抗血栓治疗兼容。

Res Rep Urol. 2017 Dec 6;9:225-232. doi: 10.2147/RRU.S146180. eCollection 2017.

Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.与促性腺激素释放激素激动剂相比，地加瑞克治疗晚期前列腺癌的系统评价和荟萃分析。

Med J Islam Repub Iran. 2016 Jan 9;30:317. eCollection 2016.

Radiotherapy for high-risk prostate cancer.高危前列腺癌的放射治疗。

Nat Rev Urol. 2015 Mar;12(3):145-54. doi: 10.1038/nrurol.2015.25. Epub 2015 Feb 24.

Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.用于治疗激素敏感性转移性前列腺癌的全身治疗：从间歇性雄激素剥夺疗法到化疗。

Curr Urol Rep. 2015 Mar;16(3):13. doi: 10.1007/s11934-015-0486-x.

Evaluation of histopathological findings at the injection site following degarelix administration.戈舍瑞林给药后注射部位组织病理学结果评估。

Support Care Cancer. 2015 May;23(5):1377-81. doi: 10.1007/s00520-014-2483-x. Epub 2014 Oct 31.

本文引用的文献

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.用促黄体生成素释放激素激动剂治疗的前列腺癌患者的肿瘤生长抑制

Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658-62. doi: 10.1073/pnas.79.5.1658.

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.促性腺激素释放激素类似物治疗晚期前列腺癌。

Br Med J (Clin Res Ed). 1983 Apr 23;286(6374):1309-12. doi: 10.1136/bmj.286.6374.1309.

Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?促黄体生成素释放激素激动剂布舍瑞林对晚期前列腺癌患者睾酮生成的持续抑制作用。一种新的治疗方法？

Lancet. 1982 May 15;1(8281):1097-9. doi: 10.1016/s0140-6736(82)92279-6.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验